News

MPN Landmark Survey funded by Incyte Corporation has been released

2017 Winners of the MPN Challenge Grant announced

Five projects focused on MPN research

Digital Sherpa Workshops

Join Patient Empowerment Network and MPN Research Foundation for Digital Sherpa Series

Follow up on the CALR mutation discovery

Dr. Hasselbach describes CALR as an immunotherapy target in new Leukemia submission.

BREAKING NEWS

AOP Orphan and PharmEssentia announces its latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

Congratulations to Dr. Mesa on his Exciting Move

Dr. Mesa move to UT Health Center

The MPN Challenge RFP is now open

Apply for a grant now

Pacritinib taken off FDA clinical hold.

CTI BioPharma will start a new trial, PAC203 for Myelofibrosis

Phase 2 study combines Ruxolitinib and Decitabine for people with MPN

Share your experience with Essential Thrombocythemia (ET) to help shape the future of treatment

This research study is by QuintilesIMS (sponsored by Incyte Corporation) Background QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients. QuintilesIMS plans to interview patients who have been diagnosed with ET one‐on‐one over the phone. QuintilesIMS is looking for interested people to share what they have gone through since being diagnosed with ET. Purpose The overall purpose of the study is to learn which symptoms of ET are the most common, and how these symptoms typically affect the lives of patients like you who live with the disease. This understanding may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of disease treatments. It also may help patients and their families by highlighting the consequences of the disease that most need greater attention, possibly leading to the development of new programs and support services.

MPN highlights from ASH's annual meeting

MPN highlights from ASH's annual meeting